Oramed Pharmaceuticals (ORMP) Share-based Compensation (2010 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Share-based Compensation came in at $1.7 million in Q1 2026, down 20.69% YoY from $2.2 million in Q1 2025, and up 20.22% on a QoQ basis from $1.4 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Share-based Compensation (2010 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 17 years of Share-based Compensation data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Share-based Compensation fell 20.69% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 4.2% YoY) and the FY2025 annual result came in at $5.2 million, up 28.86% from the prior year.
- Share-based Compensation grew to $1.7 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.9 million in Q3 2022 to a low of -$8.2 million in Q4 2022.
- A 5-year average of $417294.1 and a median of $1.2 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 194.05% — and 2024, when it jumped 641.04%.
- Tracing ORMP's Share-based Compensation over 5 years: stood at -$8.2 million in 2022, then soared by 116.72% to $1.4 million in 2023, then slipped by 11.05% to $1.2 million in 2024, then climbed by 18.75% to $1.4 million in 2025, then gained by 20.22% to $1.7 million in 2026.
- The last three Share-based Compensation figures came in at $1.7 million (Q1 2026), $1.4 million (Q4 2025), and $719000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Oramed Pharmaceuticals | 196.17 Mn | 196.17 Mn | - | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 Mn |
| Jun 30, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.74 Mn |
| Mar 31, 2026 | 1.74 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | 719,000.00 |
| Sep 30, 2025 | 719,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 2.19 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 286,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Jun 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.28 Mn |